New Windsor, NY, United States


New Windsor, NY, United States
Time filter
Source Type

Wollocko H.,OXYVITA Inc. | Wollocko B.M.,OXYVITA Inc. | Wollocko J.,OXYVITA Inc. | Grzegorzewski W.,University of Warmia and Mazury | Smyk L.,University of Warmia and Mazury
Artificial Cells, Nanomedicine and Biotechnology | Year: 2017

Uncontrolled haemorrhage is one of the leading causes of death. This issue is present in controlled environments, such as hospitals, as well as pre-hospital and remote locations. Treatment is more challenging in remote locations where there is a lack of effective products to deliver oxygen and control coagulation. Poorly treated haemorrhage can lead to rapidly deteriorating bodily conditions that can result in organ failure and tissue death. Thus, the availability of products to support oxygen delivery to tissues and coagulation processes within the body is essential for the effective treatment of severe haemorrhage, particularly in out-of-the-hospital settings. The presence of such products would fill the gap that is currently present in emergency treatment. Promising results of an ex-vivo study on a novel haemoglobin-based oxygen carrier OxyVita®C with coagulation capacity (OVCCC) are presented in this article. The proprietary protein protection technology allows for the powderization of protein components without changes in their characteristics and physiological activity. This technology was applied to the oxygen carrier OxyVita®C, to plasma and to platelets. The functionality of all tested components, as well as a mixture of OxyVita®C and platelets, was studied. The results suggest future clinical trials investigating the powderization of OVCCC, plasma and platelets are warranted. The development of this powderization method offers a huge advancement into a field in which no viable products exist. © 2017 Informa UK Limited, trading as Taylor & Francis Group

Harrington J.P.,State University of New York at New Paltz | Orlig K.,State University of New York at New Paltz | Zito S.L.,State University of New York at New Paltz | Wollocko J.,OXYVITA Inc. | Wollocko H.,OXYVITA Inc.
Artificial Cells, Blood Substitutes, and Biotechnology | Year: 2010

A zero-linked polymeric hemoglobin (OxyVita Hb) has been developed for application as an acellular therapeutic hemoglobin-based-oxygen-carrier (HBOC). For effective and safe oxygen binding, transport and delivery, an HBOC must meet essential molecular requirements related to its structural integrity and redox stability. OxyVita™ is a super polymer possessing an average M.wt. of 17 × 106 Da. Structural integrity was determined by unfolding studies of OxyVita™ in the presence of increasing concentrations of urea. The unfolding midpoints (D1/2) of different preparations of OxyVita™ (solution and powder forms) were compared to Lumbricus Hb (LtHb) and Arenicola Hb (ArHb), natural acellular polymeric hemoglobins, which are serving as models for an effective and safe acellular HBOC. Reduction studies of OxyVita Hb using endogenous reducing agents were also investigated. Results from these studies indicate that: 1) OxyVita Hb exhibits greater resistance to conformational change than either LtHb or ArHb in the reduced (oxyHb) state; and 2) the reduction of met OxyVita Hb to oxyHb occurs slowly in the presence of either ascorbic acid (70% reduction in 560 min.) or β-NADH (40% reduction in 90 min.). These studies provide consistent evidence that OxyVita Hb possesses physiochemical properties that exhibit structural integrity and redox behavior necessary for functioning as an effective and safe HBOC within clinical applications. These results are in agreement with observations made by other investigators as to the reduction in heme-loss of OxyVita Hb, essential for the reversible binding/release of molecular oxygen within the circulatory system. © Informa UK Ltd.

Harrington J.P.,State University of New York at New Paltz | Harrington J.P.,OXYVITA Inc. | Wollocko J.,OXYVITA Inc. | Kostecki E.,OXYVITA Inc. | Wollocko H.,OXYVITA Inc.
Artificial Cells, Blood Substitutes, and Biotechnology | Year: 2011

OxyVita-zero-link polymerized hemoglobin (OxyVita Hb) is a novel generation hemoglobin based oxygen carrier (HBOC). Our focus in this paper is to address the question of "Why is OxyVita Hemoglobin different than the previous generation of HBOCs?" Several critical related topics will be discussed: 1) OxyVita's unique chemistry; 2) the introduction of a viable powder form of OxyVita hemoglobin for dissolution in IV water or other IV fluids; 3) the physiochemical characteristics of OxyVita hemoglobin preparations; 4) the ability to formulate different products based upon specific applications; and 5) the important storage properties essential for use in a wide range of geographical locations. © 2011 Informa Healthcare USA, Inc.

PubMed | State University of New York at New Paltz, University of Georgia and OXYVITA Inc.
Type: | Journal: Artificial cells, nanomedicine, and biotechnology | Year: 2016

A study was conducted to compare the resistance to heme exposure between myoglobin, bovine hemoglobin, and OxyVita

PubMed | State University of New York at New Paltz and OXYVITA Inc.
Type: Journal Article | Journal: Journal of functional biomaterials | Year: 2014

OxyVita Hb is a new generation hemoglobin based oxygen carrier (HBOC) produced through modification of a zero-linked polymerization mechanism using activators which incorporate cross-linked bovine tetramer hemoglobin into super-polymeric macromolecules (Average molecular weight = 17 MDa) for the purpose of oxygen delivery when whole blood or packed red cells are not available. This molecular design approach was generated in order to address several fundamental biochemical and physiological weaknesses of previous generations of HBOCs. Observation during pre-clinical and clinical studies provided evidence that these early generation acellular HBOCs were directly associated with loss of retention within the circulatory system, extravasation across endothelial tissue membranes due to their small molecular size leading to arterial and venous vasoconstriction with coupled increases in mean arterial pressure (MAP). The inherent increase in molecular size and structural stability of the OxyVita Hb is a direct response to addressing these serious weaknesses that have occurred during the evolution of HBOC development within the past two decades. The nature of the zero-linked synthetic route eliminates any chemical linkers remaining in the product, eliminating side reaction concerns, such as reversibility and decomposition due to weak chemical bonds, dependency on temperature and pressure, and residual toxicity.

Harrington J.P.,OXYVITA Inc. | Wollocko H.,OXYVITA Inc.
Journal of Artificial Organs | Year: 2010

Hemoglobin-based oxygen carriers (HBOC) are being developed to provide the oxygen necessary in clinical situations when whole blood is not available. The safety and effectiveness of each HBOC must be determined before clinical approval. In the past several years animal studies have been conducted with zero-linked polymers to evaluate their effectiveness at delivering oxygen in vivo. Studies have addressed issues associated with interstitial extravasation, cerebral ischemia and blood flow, resuscitation, and coagulation interactions. Several of the investigations reviewed are based on early preparations of zero-linked polymerized bovine hemoglobins (ZL-HbBv), which contained a wide range of high-molecular-weight polymers. Recent studies using the Oxyvita product OxyVita Hb, which contains a more homogenous population (97%) of large-molecular-weight species (∼17 MDa), are also included in this review. © 2010 The Japanese Society for Artificial Organs.

OXYVITA Inc. | Date: 2013-08-27

Pharmaceutical product, namely, blood substitute for human and veterinary use.

Loading OXYVITA Inc. collaborators
Loading OXYVITA Inc. collaborators